The pharmaceutical industry is strongly opposed to the government's plan to expand drug price reference countries. Although the Ministry of Health and Welfare says it has gone through a sufficient discussion process, the industry is strongly criticizing it as a one-sided push. The revision of the HIRA's administrative notice on the 21st of last month calls for expanding the comparative reference countries of PE drugs to two countries. It is to add Canada and Australia to the current reference countries such as the United States, Japan, the United Kingdom, Germany, France, Italy, and Switzerland. On the 5th, the KRPIA clarified its opposition that the amendment seriously undermines access to new drugs for patients with